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PregnancyAbstract Anaemia during pregnancy is most commonly observed and highly prevalent in South-
East Asia. Various effective programmes have been laid down for its management, mainly daily
supplementation of iron folic acid (IFA) tablets. Following the same, standard obstetrical practice
has included the IFA supplementation without requiring the determination of iron deﬁciency. In
this study, a total of 120 primigravida (N= 60; non-anaemic (Hb > 11 g/dl) and N= 60 anaemic
(Hb = 8–11 g/dl)) were selected among those attending the Antenatal Clinic in Department of
Obstetrics and Gynaecology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi,
India. They were supplemented with daily and weekly IFA tablets till 6 weeks postpartum. Corre-
sponding changes in haemoglobin level on advance of pregnancy, side effects and compliancein; IFA,
ceptors;
Effectiveness of weekly iron folic acid supplementation 725associated with daily and weekly IFA supplementation and its associations with iron status markers
were studied. The inﬂammatory markers were also estimated. The statistical signiﬁcance level
(p< 0.05) between the groups were assessed by applying unpaired t-test using SPSS (version
16.0). The obtained results publicized the salutary role of daily IFA supplementation in improving
the haemoglobin level and iron status markers in anaemic pregnant women though the levels could
not reach up to the non-anaemic haemoglobin levels. However, weekly IFA supplementation seems
to be a better approach in non-anaemic pregnant women where almost comparable results were
obtained in terms of haematological parameters, gestation length and birth weight.
Conclusion: Weekly IFA supplementation found to be as effective as daily supplementation in
iron sufﬁcient non-anaemic pregnant women whereas anaemic pregnant women should be pre-
scribed daily IFA supplementation irrespective of iron replete/deplete state.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Almost all over the world daily oral iron supplementation is
routinely prescribed during the pregnancy irrespective of
deplete or replete iron status at pre-conception or post-
conception and the average dose range is 60–120 mg supple-
mental iron per day as recommended by The International
Anaemia Consultative Group (Stoltzfus and Dreyfuss, 1999).
The upper dose range is recommended where there is a high
prevalence of anaemia among pregnant women. In India, anae-
mia is highly prevalent in pregnant as well as non-pregnant
women (>50% are anaemic) (De Benoist et al., 2008) that
resulted in 40% of maternal deaths (Kalaivani, 2009).
Iron deﬁciency is one of the underlying causes of anaemia
during pregnancy (De Benoist et al., 2008) and is one of the
15 leading contributors to the global burden of disease
(WHO and CDCP, 2004). Regulation of iron is a highly
sophisticated phenomenon where its imbalance could result
into signiﬁcant morbidity and mortality. The disturbed intri-
cate balance during iron regulation may either result in iron
deﬁciency or iron overload, out of which iron deﬁciency is
most commonly observed (Zimmermann and Hurrell, 2007).
Iron deﬁciency anaemia is the most common nutritional disor-
der prevalent both in developed and developing countries par-
ticularly in pregnant women of developing countries (WHO,
2001). This is due to iron deﬁcit intake of diet that could not
meet the increased iron demand for the developing foetus
(Zimmermann and Hurrell, 2007). According to World Health
Organization (WHO, 2001) around 2 billion people who count
approximately 30% of the world population is anaemic; preg-
nant women contributes approximately 41.8% of this anaemic
polulation (De Benoist et al., 2008).
The most common strategy for the management of this
staggering situation is to start oral iron supplementation dur-
ing pregnancy. In India, a National Nutrition Policy was
adopted in 1993 to reduce prevalence of anaemia and the sup-
plementation interventions include daily supplementation of
FeSO4 containing 100 mg elemental iron tablet and 500 lg
folic acid for 100 days during pregnancy followed by the same
dose for 100 days in the postpartum period (Guidelines for
control of iron deﬁciency anaemia, 2013).
During the advance of pregnancy, plasma volume expands
resulting in the decreased haematocrit and Hb levels resulting
in the ﬂuctuations in the values. Thus, the reliability of Hb
measurement and haematocrit diminished (Bentley, 1985).Ferritin level, an indicator of iron storage decreased during
the gestation but its level was found elevated in inﬂammatory
conditions, being an acute phase reactant. Thus, measurement
of sTfR along with these parameters would help to detect iron
deﬁciency state more precisely because neither is it an acute
phase reactant (Skikne, 1998) nor inﬂuenced by hemodilution
during pregnancy (Akinsooto et al., 2001). The inﬂammatory
markers like cortisol and high sensitivity C-reactive protein
were also studied to ensure the changes in the level of iron
markers were true reﬂection of oral iron supplementation
and not inﬂuenced by inﬂammation. Erythropoietin hormone
responsible for the expansion of red cell mass whose level con-
tinuously increased during the pregnancy that led to the rise in
Hb concentration (Barton et al., 1994; McMullin et al., 2003;
Milman et al., 1997). Thus measurement of aforementioned
markers could reﬂect the complete iron proﬁle of the body.
Although, the effect of daily versus weekly IFA supple-
mentation on iron status markers during pregnancy has been
studied scanty information is available about the amount and
regularity of IFA intake in comparison with iron status
markers level and also the side-effects associated with differ-
ent supplementation schemes. Owing to these, the present
study was designed to examine the impact of daily versus
weekly oral iron supplementation in improving the iron
status makers, Hb levels, birth weight and effect on erythro-
poietin level, gestation length and mode of delivery in
anaemic/non-anaemic pregnant women during gestation and
postpartum period.
2. Material and methods
2.1. Subjects
The present study comprised a total of 120 pregnant women in
their early second trimester (13–16 weeks of gestation) who are
yet to start oral iron supplementation. Out of 120, 60 were
non-anaemic (Hb > 11 g/dl) women and 60 were anaemic
(Hb = 8–11 g/dl) women. The subjects were selected among
those attending the Antenatal Clinic in Department of Obstet-
rics and Gynaecology, All India Institute of Medical Sciences,
Ansari Nagar, New Delhi, India. Pregnant women fulﬁlling
the subject selection criteria, having no chronic morbidity,
20–30 years old primigravida, and belong to middle socio-
economic group willing to participate (informed consent
obtained) were enrolled in the study. Exclusion criteria include
726 H. Shankar et al.history of any metabolic disease like diabetes mellitus, malig-
nancy and heart disease, infectious diseases like tuberculosis,
HIV, endocrine disorders or taking any iron preparations dur-
ing or from past 3 months.
2.2. Randomization
The participants fulﬁlling the screening criteria were allocated
to anaemic group on the basis of Hb range between 8–11 g/dl
and non-anaemic group (Hb > 11 g/dl). After informed con-
sent process, envelopes containing random number slips for
60 pregnant women in daily and 60 pregnant women in weekly
arm prepared at Indian Council of Medical Research provided
to the participating centre were opened for allocation in daily
and weekly arm. Random numbers were generated in a ratio of
1/1 by means of a customized computer programme. Accord-
ing to the serial number of the enrolled subject, one sealed
envelope containing a slip with instructions for random alloca-
tion of subject to either daily or weekly arm was opened for
each subject. The Participants were assigned the iron supple-
ment regimen accordingly. The enrolled participants were cat-
egorized into two groups as follows:
Group 1: pregnant non-anaemic (Hb > 11 g/dl) women
(N= 60).
Group 2: pregnant anaemic (Hb = 8–11 g/dl) women
(N= 60).
Informed consent was obtained from each subject and the
study was approved by the Institutional Ethics Committee of
All India Institute of Medical Sciences, New Delhi, India.
2.3. Study design
All the enrolled participants (anaemic and non-anaemic preg-
nant women) were dewormed by giving single dose of Alben-
dazole 400 mg to be consumed at night on the day of
enrolment. The enrolled participants were asked to fast over-
night and on the next morning venous blood sample was
drawn from anticubital vein in supine position followed by
refreshments. Likewise, second sample (3 months after ﬁrst
sampling) and third sample (6 weeks postpartum) were
obtained in a similar manner.
According to random allocation of slip instructions, partic-
ipants were given either one tablet of FeSO4 containing 100 mg
elemental iron and 500 lg folic acid (iron folic acid tablet/IFA
tablet) till 6 weeks postpartum daily or two IFA tablets weekly
till 6 weeks postpartum. Thus, both the groups i.e. group 1 and
2 further subdivided into daily IFA supplementation group
(DISG; N= 30) and weekly IFA supplementation group
(WISG; N= 30). There was no placebo group in the study
as iron deﬁciency is widely prevalent and denying iron to
any participant was not possible since daily iron supplementa-
tion is included in the Indian National Programme.
2.4. Sample collection
6 ml venous blood was taken from each participant and serum
separated by centrifuging the blood in clot activator tubes at
3000 rpm for 15 min. Different aliquots were prepared and
stored in 80 C till further analysis.2.5. Analytical estimation
2.5.1. Measurement of blood index parameters
Blood haemoglobin (Hb) was determined by using the
Cyanomethemoglobin method (Cook, 1985). Haematocrit
(Hct), mean corpuscular volume (MCV), mean corpuscular
haemoglobin (MCH), red blood cell (RBC) counts were deter-
mined by using Sysmax A-380 automated cell counter.
2.5.2. Measurement of iron and inflammatory markers
Serum was analyzed for ferritin, soluble transferrin receptors
(sTfR), erythropoietin, cortisol and high sensitivity
C-reactive protein (HsCRP) and levels were measured using
competitive ELISA kits. The results were compared with those
of the standard curve obtained from the calibrators run
simultaneously with the study samples for each parameter.
Inductively Coupled Plasma-Atomic Emission Spectroscopy
(ICP-AES) (JY 2000 2, Jobin Horiba) technique was used
for measuring the serum concentration of iron.
2.6. Statistical analysis
Data were expressed as mean ± SE. Statistical analysis was
performed using Statistical Package for Social Sciences (SPSS)
version 20.0. In order to evaluate signiﬁcance level between the
groups, unpaired t-test was applied and the statistical signiﬁ-
cance level (p< 0.05) was also determined using a one way
analysis of variance (ANOVA) followed by Tukey’s multiple
comparison tests. Repeated measure ANOVA was also applied
to check the level of signiﬁcance as each subject was measured
for a particular variable at three time points.
3. Results and discussion
The present study comprised non-anaemic and anaemic primi-
gravida with age group between 19–30 years, BMI ranged
18–22 kg/m2, belonging tomiddle socio-economic status between
11 and 25 on Kuppuswamy’s socioeconomic status scale.
3.1. Daily versus weekly IFA supplementation in non-anaemic
pregnant women
3.1.1. Amount and regularity of IFA tablets intake from baseline
to second visit
The results of the study showed that the mean number of IFA
tablets intake was 88.93 in DISG compared to 24.32 in WISG.
The regularity of IFA tablets intake found to be 100% as
highly regular in WISG compared to DISG where 89.2%
showed <3 IFA tablets intake defaults and 10.7% were irreg-
ular. Although the symptoms due to IFA tablets intake were
more commonly observed in WISG compared to DISG but
the severity of the symptoms was mild. The percentage of
women who withheld IFA due to side effects was 2.6-fold high
in DISG with comparatively low percentage of women who
withheld IFA due to forgetfulness than WISG (Table 1).
3.1.2. Amount and regularity of IFA tablets intake from second
visit to 6 weeks postpartum
The mean IFA tablets intake was found to be 124.7 in DISG as
compared to 33.7 in WISG where 95.8% women were highly
Table 1 Amount, regularity and symptoms of iron folic acid tablets (IFA) intake.
IFA
supplementation
groups
Number of IFA
tablets consumed
(Mean ± SE)
Regularity
of IFA
tablets
consumed
Subjects not taken
IFA due to side eﬀect
(number of times)
Subjects not taken IFA due to
forgetfulness (number of
times)
Symptoms due to IFA
intake- subjects
Severity
Non-
anaemic
WISG
Baseline
to second
visit
24.32 ± 0.29 100% 4% (one time) 12% (one time) Nausea 4%
Vomiting 16%
Abdomen pain 8%
Headache-4%
Mild
Mild
Mild
Mild
Second
visit till
6 weeks
PP
33.79 ± 1.01 95.8%
4.1%
8.3% (50% two times
and 59% four times)
16.6% (two times) Vomiting-16.6%
Constipation-4.1%
Mild
Mild
Non-
anaemic
DISG
Baseline
to second
visit
88.93 ± 0.89 89.2%
10.7%
10.7% (66.6% one
time and 33.3% two
times)
7.1% (50% one time and 50%
for two times)
Vomiting-7.1%
Constipation-3.5%
Loss of appetite-3.5%
Mild
Mild
NIL
Second
visit till
6 weeks
PP
124.7 ± 2.47 88.0%
12.0%
4.0% (one time) 20.0% (40% three times and
20% nine times, 20% ten
times and 20% ﬁfteen times)
Constipation-4% Mild
Anaemic
WISG
Baseline
to second
visit
24.20 ± 0.35 100% NIL NIL Distention abdomen-
10% Constipation-10%
Vomiting-10%
Mild
Moderate
Mild
Second
visit till
6 weeks
PP
31.60 ± 3.57 62.5%1
25%2
12.5%3
12.5% (six times) 37.5% (33.3% one time,
33.3% ﬁve times and 33.3%
seven times)
Nausea-12.5% cases
Vomiting-12.5%
Mild
Moderate
Anaemic
DISG
Baseline
to second
visit
89.44 ± 1.35 77.7%
22.2%
NIL 22.2% (50% ﬁve times and
50% six times)
Acidity-11.1% NIL
Second
visit till
6 weeks
PP
116.3 ± 4.37 66.6%
22.2%
11.1%
11.1% (30 times) 55.5% (40% two times and
20% three times, 20% ﬁve
times and 20% seven times)
Fever-11.1% Moderate
WISG – weekly IFA supplementation group; DISG – daily IFA supplementation group; PP – postpartum.
1 Highly regular < 3 IFA tablets intake defaults.
2 Irregular = 3–7 IFA tablets intake defaults.
3 Highly irregular > 7 IFA tablets intake defaults.
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and 12% highly irregular in DISG. The percentage of women
who withheld tablets due to side effects was more than double
in WISG (8.3% versus 4%) whereas this group comprised
comparatively less percentage of women who withheld the
IFA tablets due to forgetfulness (16.6% versus 20%). The per-
centage of women with symptoms like mild vomiting and con-
stipation was observed more in WISG than DISG (Table 1).
3.1.3. Haematological markers and delivery outcomes
All the haematological parameters (Hct, RBC count, MCV and
MCH) found comparable in both the supplementation groups,
however statistically signiﬁcant difference was observed while
analyzing these parameters using repeated measure ANOVA
in DISG {(Hb: F (2,48) = 7.78; p= 0.001); (Hct: F (2,44)
= 8.23; p= 0.001); (RBC count: F (2,46) = 21.53;
p= 0.000); (MCV: F (2,44) = 3.761; p= 0.035); (MCH: F
(2,46) = 4.92; p= 0.012)} and WISG {(Hb: F (2,50) = 7.77;
p= 0.001); (Hct: F (2,50) = 8.90; p= 0.000); (RBC count:
F (2,50) = 14.43; p= 0.000); (MCH: F (2,50) = 7.90;
p= 0.001)}. In addition there was no signiﬁcant differenceobserved in gestation length or birth weight (Table 2). How-
ever, the percentage of women underwent caesarean delivery
was found to be high in WISG compared to DISG (48% versus
28.5% i.e. 1.68-fold high) and that group was also found to
have signiﬁcantly low Hb at postpartum compared to DISG
(p< 0.05).
3.1.4. Iron status markers
The effect of daily and weekly oral IFA supplementation is
summarized in Table 3 where the non-signiﬁcant difference
was observed in most of the studied parameters. The signiﬁ-
cant difference was obtained in haemoglobin measured at post-
partum in DISG (p< 0.05) which is in relation with the serum
levels of ferritin (p< 0.01) and iron (p< 0.05) as compared to
WISG. However, a signiﬁcant increase in serum level of iron
was found in DISG at second visit also (p< 0.01). DISG
group showed signiﬁcant change (p< 0.01) in the studied iron
status marker {(Ferritin: F (2,50) = 31.29; p= 0.000)} and
inﬂammatory markers {(HsCRP: (F (2,50) = 10.91;
p= 0.000); (cortisol: F (2,50) = 3.80; 0.029)} when analyzed
in longitudinal manner, whereas iron and sTfR changed
Table 2 Daily versus weekly IFA tablets supplementation affecting haematological parameters, birth weight, gestation length and
mode of delivery.
Parameters Non anaemic pregnant women Anaemic pregnant women
DISG WISG DISG WISG
Haemoglobin (g/dl) Baseline 12.11 ± 0.12 12.06 ± 0.12 10.12 ± 0.14 9.92 ± 0.12
Second visit 11.46 ± 0.14 11.28 ± 0.17 10.88 ± 0.24 9.72 ± 0.25
Pre delivery 11.84 ± 0.17 11.56 ± 0.20 11.08** ± 0.26 9.91 ± 0.28
Postpartum 12.33* ± 0.22 11.65 ± 0.23 11.62 ± 0.23 11.57 ± 0.44
Haematocrit (%) Baseline 35.52 ± 0.37 35.48 ± 0.37 30.96 ± 0.54 31.04 ± 0.58
Second visit 33.46 ± 0.38 33.32 ± 0.46 31.33 ± 0.76 28.50 ± 1.20
Postpartum 35.23 ± 1.39 35.33 ± 0.67 34.92 ± 0.60 33.17 ± 1.90
RBC count (106/ll) Baseline 4.09 ± 0.05 4.11 ± 0.07 3.67 ± 0.12 3.61 ± 0.12
Second visit 3.71 ± 0.05 3.71 ± 0.04 3.70 ± 0.10 3.35 ± 0.14
Postpartum 4.16 ± 0.08 4.04 ± 0.12 4.05 ± 0.12 3.97 ± 0.25
MCV (ﬂ) Baseline 86.92 ± 0.88 86.83 ± 1.40 86.67 ± 3.49 88.00 ± 2.71
Second visit 90.46 ± 0.90 89.94 ± 1.22 84.95 ± 2.88 85.45 ± 2.71
Postpartum 84.56 ± 3.06 88.37 ± 1.88 86.76 ± 2.32 84.33 ± 2.40
MCH (pg/cell) Baseline 29.64 ± 0.31 29.56 ± 0.55 28.55 ± 1.32 28.30 ± 0.99
Second visit 31.17 ± 0.41 30.54 ± 0.44 28.73 ± 1.07 29.04 ± 1.01
Postpartum 29.70 ± 0.52 29.37 ± 0.62 28.90 ± 0.92 28.76 ± 1.05
Gestation length (days) 270.6 ± 1.97 269.5 ± 2.04 271.3 ± 2.85 270.5 ± 2.64
Vaginal delivery (%) 71.5 52 71.5 69.3
Caesarean delivery (%) 28.5 48 28.5 30.7
Birth weight (gm) 2825 ± 89.71 2841 ± 92.26 2819 ± 139.8 2918 ± 86.78
DISG – daily iron folic acid supplementation group; WISG – weekly iron folic acid supplementation group; RBC count – red blood corpuscle
count; MCV – mean corpuscular volume; MCH – Mean corpuscular haemoglobin.
Data expressed as mean ± SE; Signiﬁcance *P< 0.05, **P< 0.01.
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more, the postpartum period referred to as the period of lowest
iron deﬁciency risk (National Research Council, 1990) as the
expanded red cell mass contracts at delivery resulting in the
increased body iron stores (Bothwell, 1995) and continuing
the IFA tablets daily might contribute to the excessive
increased serum iron levels and reserves of the body that was
found in the current study.
Though, weekly IFA supplementation resulted in anaemia at
postpartum (anaemia deﬁned at postpartum; Hb < 12.3 g/dl
(Bentley, 1985)) without iron deﬁciency (iron deﬁciency deﬁned
at postpartum; serum ferritin < 15 ng/ml (Milman et al., 2000))
and signiﬁcant decrease in serum level of iron at second visit; still
the decline was well above the cut-off levels deﬁned for the deﬁ-
ciency of respective markers and also there were no marked
differences obtained between DISG and WISG in rest of the
studied parameters. All the studied parameters viz. iron
(F (2,20) = 3.71; p= 0.043), HsCRP (F (2,52) = 14.95;
p= 0.000) and cortisol (F (2,52) = 16.18; p= 0.000) except
sTfR and ferritinwere signiﬁcantly different inWISGwhen ana-
lyzed by repeated ANOVA. Furthermore, the pre-delivery Hb
was comparable in both the supplementation groups stating
weekly supplementation is as effective as daily supplementation
in improving Hb level till term delivery. The body iron reserves
in terms of sTfR, ferritin and Hb were well maintained up to the
initiation of third trimester in both the supplemental schedules
(Table 3).
Thus, it can be summarized that weekly IFA supplementa-
tion could be a better approach in terms of cost effectiveness
and producing comparable results in non-anaemic pregnantwomen. It was noted that it may contribute to the incidence
of mild to moderate side effects and slight increase chances
of caesarean delivery but the results may be confounding due
to multiple factors.
3.2. Daily versus weekly IFA supplementation in anaemic
pregnant women
3.2.1. Amount and regularity of IFA tablets intake from baseline
to second visit
The mean of IFA tablets consumed was 89.4 in DISG with
77.7% women being highly regular and 22.2% irregular as
compared to 24.2 in WISG where 100% were found highly reg-
ular. Though the symptoms that appeared due to IFA intake
were more in WISG it did not affect the compliance rate,
which might be due to the less severity of the observed symp-
toms. However, the percentage of women who withheld IFA
tablets intake due to forgetfulness was 22.2% in DISG whereas
this percentage found to be nil in WISG (Table 1).
3.2.2. Amount and regularity of IFA tablets intake from second
visit to 6 weeks postpartum
During this period, the mean IFA tablet intake was 116.3 in
DISG with regularity of intake being 66.6% highly regular,
22.2% irregular and 11.1% highly irregular as compared to
31.6 in WISG where 62.5% were found highly regular, 25%
irregular and 12.5% highly irregular. In DISG, 11.1% women
withheld IFA due to side effects and 55.5% withheld due to
forgetfulness compared to 12.5% and 37.5% in WISG
Table 3 Daily versus weekly iron supplementation affecting the iron status markers.
Parameters Non-anaemic pregnant women Anaemic pregnant women
DISG WISG DISG WISG
Haemoglobin (g/dl) Baseline 12.11 ± 0.12 12.06 ± 0.12 10.12 ± 0.14 9.92 ± 0.12
Second visit 11.46 ± 0.14 11.28 ± 0.17 10.88 ± 0.24 9.72 ± 0.25
Pre delivery 11.84 ± 0.17 11.56 ± 0.20 11.08 ± 0.26** 9.91 ± 0.28
Postpartum 12.33 ± 0.22* 11.65 ± 0.23 11.62 ± 0.23 11.57 ± 0.44
S. Ferritin (ng/ml) Baseline 34.52 ± 5.12 26.69 ± 4.12 35.39 ± 7.18 34.77 ± 4.59
Second visit 53.08 ± 6.78 33.51 ± 5.49 51.99 ± 9.91 34.38 ± 7.63
Postpartum 132.3 ± 21.33** 37.04 ± 9.16 135.7 ± 25.74* 52.24 ± 12.17
S. Iron (lg/dl) Baseline 115.5 ± 6.57 110.7 ± 6.96 97.99 ± 5.79 91.04 ± 4.88
Second visit 133.7 ± 8.42** 102.7 ± 7.62 119.5 ± 7.63*** 73.29 ± 6.26
Postpartum 132.7 ± 14.48* 97.2 ± 6.76 96.9 ± 6.29 96.80 ± 11.10
S. sTfR (lg/ml) Baseline 1.87 ± 0.28 1.78 ± 0.23 1.49 ± 0.33 1.41 ± 0.25
Second visit 1.46 ± 0.13 2.16 ± 0.39 1.73 ± 0.29 1.95 ± 0.29
Postpartum 1.36 ± 0.15 1.44 ± 0.35 1.69 ± 0.36 1.67 ± 0.31
S. EPO (mIU/ml) Baseline 18.40 ± 1.74 20.45 ± 10.20 15.77 ± 2.70 14.17 ± 3.83
Second visit 27.41 ± 5.47 30.33 ± 6.63 31.94 ± 6.21 68.67 ± 15.61a
Postpartum 13.33 ± 3.5 15.00 ± 2.91 12.00 ± 1.67 13.00 ± 1.66
S. HsCRP (mg/l) Baseline 4.84 ± 0.88 4.33 ± 1.03 5.53 ± 1.05 4.16 ± 0.65
Second visit 7.60 ± 1.30 6.26 ± 1.28 3.31 ± 0.76 4.28 ± 1.32
Postpartum 1.65 ± 0.60 2.33 ± 0.56 8.40 ± 1.39b 5.05 ± 1.13
S. Cortisol (ng/ml) Baseline 98.09 ± 20.37 97.13 ± 12.88 134.0 ± 11.76 112.8 ± 11.02
Second visit 155.5 ± 20.90 155.6 ± 12.19 202.7 ± 13.32 185.9 ± 20.57
Postpartum 87.06 ± 12.73 98.05 ± 12.63 106.1 ± 15.19 79.68 ± 14.48
DISG – daily iron folic acid supplementation group; WISG – weekly iron folic acid supplementation group; S. sTfR – serum soluble transferring
receptor; S. EPO – serum erythropoietin; S. HsCRP – serum high sensitivity C-reactive protein.
Data expressed as mean ± SE; Signiﬁcance *P< 0.05, **P< 0.01, ***P< 0.0001, aP 6 0.06, bP 6 0.09.
Effectiveness of weekly iron folic acid supplementation 729respectively. The symptoms like nausea and vomiting were
observed more in WISG as compared to DISG (Table 1).
3.2.3. Haematological markers and delivery outcomes
There was no signiﬁcant difference observed in most of the
studied haematological parameters, birth weight, gestation
length and mode of delivery (Table 2). Nevertheless, pre-
delivery haemoglobin was found to be signiﬁcantly high in
DISG compared to WISG (p< 0.01) achieving the value near
non-anaemic haemoglobin level at term. In addition, after ana-
lyzing the variables using repeated measure ANOVA, a signif-
icant change was observed in Hb (F (2,38) = 25.17;
p= 0.000); Hct (F (2,38) = 21.10; p= 0.000) and RBC count
(F (2,38) = 3.63; p= 0.036) in DISG and Hb (F (2,44) =
11.18; p= 0.000); Hct (F (2,44) = 12.90; p= 0.000) and
RBC count (F (2,42) = 5.84; p= 0.006) in WISG. The results
revealed that the signiﬁcant change in haematological param-
eters are comparable in both the groups.
3.2.4. Iron status markers
In anaemic pregnant women, both the supplementation regi-
men failed to achieve non-anaemic Hb level at studied time
interval except pre-delivery Hb where it was signiﬁcantly high
in DISG. However, it is noteworthy that most of the studied
parameters were found comparable. The signiﬁcant increase
at the postpartum serum level of ferritin (p< 0.05) was
observed in DISG, which could be explained, by non-
signiﬁcant increased level of inﬂammatory protein HsCRP
(p 6 0.09) (Table 3). Since serum ferritin being an indicatorof iron stores found to be elevated in inﬂammatory conditions
that limit its utility as a sole marker for deﬁning iron deﬁ-
ciency. Thus, it should be used along with other more sensitive
iron markers like sTfR whose level remained quite stable and
rose only in the condition of insufﬁcient iron supply to the ery-
throcytes due to exhausted iron reserves (Baynes, 1994). Fur-
thermore, the signiﬁcant difference between DISG and
WISG was also observed in serum iron level at second visit
(p< 0.0001) but again this could be the result of enhanced
erythropoiesis under the inﬂuence of erythropoietin hormone
whose level was found non-signiﬁcantly high in WISG com-
pared to DISG (p 6 0.06) (Table 3). In various studies an
inverse relation was observed between Hb and iron status with
erythropoietin hormone (Barton et al., 1994; Cook, 1985;
McMullin et al., 2003) that is similar to the current ﬁndings.
The enhanced erythropoiesis in WISG at second visit could
be explained by the activation of homoeostatic mechanism of
the body in response of low level of Hb, which in turn leads
to increased iron requirement resulting in iron depletion. How-
ever, it has been reported that the iron supplementation
imposed a check on this erythropoietic drive of the body
(Barton et al., 1994; McMullin et al., 2003). Thus it may be
inferred that weekly IFA supplementation could not provide
sufﬁcient iron needed for erythropoiesis resulting in the deple-
tion of serum iron level at second visit. While analyzing the
data using repeated measure statistical test, most of the
parameters viz. ferritin (F (2,50) = 31.29; p= 0.000); sTfR
(F (2,54) = 17.38; p= 0.000) and cortisol (F (2,54) = 30.49;
p= 0.000) were signiﬁcantly changed from baseline to 6 weeks
730 H. Shankar et al.postpartum and ferritin (F (2,54) = 26.62; p= 0.000); HsCRP
(F (2,54) = 3.60; p= 0.034); cortisol (F (2,54) = 5.55;
p= 0.006); Iron (F (2,8) = 7.20; p= 0.016) in WISG. This
shows that most of the iron and inﬂammatory markers chan-
ged during the course of pregnancy. Mainly, weekly supple-
mentation caused decline in iron markers and increase in
inﬂammatory markers.
The results of the study warrant using weekly iron supple-
mentation during anaemic pregnancy as anaemia itself con-
tributes to enhanced erythropoiesis that results in the
increased iron requirements leading to iron deﬁciency and fur-
ther iron exhaustion. Daily iron supplementation was found to
be comparatively safer approach as the Hb level was main-
tained near the cut-off value to deﬁne anaemia during
pregnancy.
4. Conclusion
The concluding remarks include that daily rather than weekly
iron supplementation is a more effective way to combat anae-
mia during pregnancy in anaemic pregnant women. However,
in non-anaemic pregnant women weekly iron supplementation
is as effective as daily dose in terms of birth weight, gestation
length and cost effectiveness but at a price of slightly more side
effects and increased chances of caesarean deliveries.
Trial registration
Clinical Trial Registry-India: CTRI/2014/10/005135 [Regis-
tered on: 22/10/2014].
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